Our Development Pipeline
TMB-002 (topical rapamycin) is being developed for the treatment of FAs in TSC. Efficacy has been demonstrated in multiple well controlled studies and dozens of published case reports for topical mTOR inhibitors that have been compounded in the past. However, there is no commercial formulation available. TMB-002 is a room temperature stable 1% formulation of rapamycin with a high level of content uniformity. A Phase 2b clinical trial of TMB-002 is currently ongoing, and targets to enroll 120 patients across 17 trial sites globally.
If you are interested in any of Timber’s ongoing clinical research programs, please contact email@example.com.